Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Not Recruiting

Trial ID: NCT04167761


The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Official Title

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Stanford Investigator(s)

Tracey McLaughlin
Tracey McLaughlin

Professor of Medicine (Endocrinology)


Inclusion Criteria:

* patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery
* history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled

Exclusion Criteria:

* allergy or intolerance to interventional medication
* currently taking any anti-diabetic medication other than metformin


drug: Ertugliflozin

drug: Glipizide

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Tracey McLaughlin, MD